PUBLIC COMPANY
saveAB2 Bio Ltd
founded 2010 · 10 employees · Lausanne, Vaud, CHupdated 1mo ago
AB2 Bio is a Phase 3 clinical-stage Swiss biotech developing therapies for severe systemic hyperinflammatory syndromes driven by IL-18. Its lead candidate, tadekinig alfa, is being advanced in IL-18 mediated rare orphan diseases including primary monogenic IL-18 driven hemophagocytic lymphohistiocytosis. The company was established in 2010 and is based at the EPFL Innovation Park in Lausanne.
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
comments(0)
5-min edit window · permanent after that